drugset
Drugs / LYT-300
last change Nov 2023 re-read 3 minutes ago

LYT-300

Investigated by
Novotech (Australia) Pty Limited · PureTech

Trials 1

today NCT05129865 · Ph 1/2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05129865 Dec 2021 → Oct 2023 — PureTech Completed Met primary

Press releases naming this drug 8 releases

DateIssuerRelease
2023-11-14 PureTech PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers puretechhealth.com ↗
2023-08-01 PureTech PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome puretechhealth.com ↗
2023-06-21 PureTech PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders puretechhealth.com ↗
2023-02-14 PureTech PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression puretechhealth.com ↗
2022-12-19 PureTech PureTech's LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers puretechhealth.com ↗
2022-06-14 PureTech PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LYT-300 puretechhealth.com ↗
2021-12-08 PureTech PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological Conditions puretechhealth.com ↗
2021-12-07 PureTech PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions puretechhealth.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as LYT-300 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05129865 ↗
Route Oral “orally administered LYT-300” NCT05129865 ↗